References
Main report (excludes cancer data commentaries)
ABS (Australian Bureau of Statistics) 2018. Population projections, Australia, 2017 (base) – 2066. ABS cat. no. 3222.0. Canberra: ABS.
AIHW (Australian Institute of Health and Welfare) 2019. BreastScreen Australia monitoring report 2018. Cancer series no.127. Cat no. CAN 128. Canberra: AIHW
Al-Marhoon M, Osman A, Kamal M and Shokier A 2011. Incidental vs symptomatic renal tumours: Survival outcomes. Arab Journal of Urology 9(1): 17–21.
Brenner H and Gefeller O 1996. An alternative approach to monitoring cancer patient survival. Cancer78:2004–10.
Day NE 1987. Cumulative rates and cumulative risk. In: Muir C, Waterhouse J, Mack T, Powell J & Whelan S (eds). Cancer Incidence in Five Continents, Vol. V (IARC Scientific Publication No. 88). Lyon: International Agency for Research on Cancer. 787–789.
Dickman PW 2004. Estimating and modelling relative survival using SAS. Stockholm: Karolinska Institutet. Viewed 26 May 2020.
Ederer F & Heise H 1959. Instructions to IBM 650 programmers in processing survival computations. Methodological note.
Fay MP, Pfeiffer R, Cronin KA, Le C & Feuer EJ 2003. Age-conditional probabilities of developing cancer. Statistics in Medicine 22(11):1837–1848.
Greenwood M 1926. The errors of sampling of the survivorship table. Reports on public health and medical subjects. Vol 33. London: Her Majesty’s Stationery Office.
Jensen O, Parkin D, MacLennan R, Muir C & Skeet R (eds) 1991. Cancer registration: principles and methods. IARC scientific publications no. 95. Lyon: IARC.
Luke C, Tracey E, Stapleton A and Roder D 2010. Exploring contrary trends in bladder cancer incidence, mortality and survival: implications for cancer research and cancer control. Internal Medicine Journal 40:357–62.
Qaseem A, Usman N, Jayaraj J S, et al. (September 02, 2019) Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site. Cureus 11(9): e5552. doi:10.7759/cureus.5552
Skuladottir H & Olsen JH 2003. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. Journal of Clinical Oncology 21(16):3035–40.
Smith D Supramaniam R, Marshall V and Armstrong B 2008. Prostate cancer and prostate specific antigen testing in New South Wales. Medical Journal of Australia 189(6): 315–18.
Vaccarella S, Franceschi S, Bray F, Wild C, Plummer M and Dal Maso L 2016. The increase in thyroid cancer may be due to an increase in medical surveillance and the introduction of new diagnostic techniques, such as neck ultrasonography. The New England Journal of Medicine 375: 614–17.
Wyld D, Wan M, Moore J, Dunn N and Youl P 2019. Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia. Cancer Epidemiology, Volume 63, 101598, ISSN 1877–7821.
Cancer data commentaries
AIHW (Australian Institute of Health and Welfare) 2012. Cancer incidence projections: Australia, 2011 to 2020. Cancer series no. 66. Cat. no. CAN 62. Canberra: AIHW.
Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R et al. (eds). 2017. Cancer incidence in five continents. Vol. XI (electronic version). Lyon, France: International Agency for Research on Cancer. Viewed June 2018, <http://ci5.iarc.fr>.
Cancer Australia 2020. What are the risk factors for pancreatic cancer?. New South Wales: Cancer Australia. Viewed 27 October 2020.
Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B (2001). Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25:1283-1289.
Downer M, Stampfer M & Cooperberg M (2017). Declining incidence rates of prostate cancer in the United States: is this good news or not? JAMA Oncology. 3(12):1623–1624.
Garg K, Rabban J (2013). Practical value of systematic and complete examination of fallopian tubes in unselected women undergoing salpingectomy for benign indications: results of a prospective study. Mod Pathol 26:276A.
Legler J, Lynn A, Gloeckler Ries, Smith M, Warren J, Heineman E, Kaplan R and Linet M 1999. Brain and Other Central Nervous System Cancers: Recent Trends in Incidence and Mortality, Journal of the National Cancer Institute, Volume 91, Issue 16, Pages 1382–1390.
McCluggage, W., Judge, M., Clarke, B. et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28, 1101–1122 (2015).
Modan B, Wagener D, Feldman J, Rosenberg M and Feinleib 1992. Increased Mortality from Brain Tumours: A combined Outcome of Diagnostic Technology and Change of Attitude toward the Elderly. American Journal of Epidemiology, Volume 135, Issue 12, Pages 1349–1357.
Piek JM, van Diest PJ, Zweemer RP et al (2001). Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 195:451-456.
Smith D Supramaniam R, Marshall V and Armstrong B (2008). Prostate cancer and prostate specific antigen testing in New South Wales. Medical Journal of Australia 189(6): 315–18.
Zhou C, Check D, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, Bray F, Cook M & Devesa S (2015). Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. International Journal of Cancer. 138(6):1388–1400.